Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

164.51 4.75 +2.97%
Market cap
$16.2B
P/E
23.0×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
7 8 6 6 4 5 7 6 3 —
P/E ratio
29.43 40.38 51.86 74.58 89.65 21.98 268.73 324.59 0.00 0.00
P/S ratio
4.93 5.82 6.82 7.73 7.11 8.53 12.49 14.28 39.55 92.53
Altman Z-Score
7.80 8.83 8.70 11.59 7.62 9.70 8.65 7.24 7.56 35.68
Altman Z″-Score (non-manufacturers)
6.21 5.61 4.58 5.40 3.70 4.35 (0.12) 1.66 (0.97) (0.53)
P/FCF ratio
18.85 24.60 35.59 35.63 34.56 41.01 74.42 84.09 0.00 0.00
Beneish M-Score
(2.64) (2.23) (1.68) (2.15) (2.60) (1.55) (1.75) (1.52) — —
P/Operating CF
36.33 56.51 104.21 80.45 1,918.35 94.43 100.99 127.57 172.16 (106.00)
P/B ratio
4.34 5.29 5.77 6.74 5.86 7.92 15.46 13.40 18.77 10.65
EV/Sales
4.61 5.60 6.57 7.38 7.11 8.44 12.24 14.54 38.72 84.07
EV/EBITDA
20.71 23.07 48.80 40.97 58.40 45.72 96.46 109.92 0.00 0.00
EV/FCF
17.61 23.66 34.27 34.04 34.60 40.55 72.91 85.67 (67.54) (27.62)
Current Ratio
3.39 3.40 2.45 2.70 3.96 5.45 1.47 8.36 10.20 10.21
Net Debt/EBITDA
(2.33) (1.88) (4.06) (3.69) (2.72) (2.50) (5.83) (4.40) 1.27 2.15
Debt/Equity
0.00 0.00 0.00 0.00 0.24 0.28 0.14 0.81 0.99 0.00
ROE
16.38% 14.16% 12.68% 10.03% 7.17% 46.20% 6.62% 4.95% (41.50%) (38.17%)
ROA
11.46% 9.79% 8.89% 6.96% 4.71% 26.79% 3.22% 2.33% (24.10%) (33.60%)
ROIC
21.83% 23.56% 13.06% 21.66% 6.42% 15.84% 84.62% 10.53% (36.36%) (1,130.99%)
Return on Tangible Assets
25.61% 26.26% 24.41% 15.86% 11.41% 46.59% 12.03% 3.09% (27.88%) (49.28%)
Average Days of Receivables
87.64 74.25 84.97 85.81 59.73 54.83 58.63 46.44 70.29 0.00
Earnings Yield
3.40% 2.48% 1.93% 1.34% 1.12% 4.55% 0.37% 0.31% (2.06%) (4.19%)
Free Cash Flow Yield
5.31% 4.07% 2.81% 2.81% 2.89% 2.44% 1.34% 1.19% (1.45%) (3.29%)
Free Cash Flow per Share
7.52 5.55 3.70 3.37 2.46 2.34 1.44 0.85 (1.15) (1.27)
Book value per Share
32.69 25.79 22.85 17.83 14.52 12.10 6.95 5.33 4.22 3.63
Free Cash Flow
748.70 557.20 361.60 322.90 233.10 217.60 132.30 76.60 (101.26) (110.28)
EV/EBIT
21.30 23.11 49.39 44.14 78.68 54.14 133.42 178.33 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026